Shortly after SARS-CoV-2 caused the COVID-19 outbreak in China, we began reviewing and implementing plans to secure our associates’ health, safety, and well-being as well as ensuring HemoCue ability to maintain essential operations and supply to customers.
This is a brief summary to bring clarity to questions and issues concerning our associates, customers and business partners worldwide. We will continue to monitor the situation closely and provide updates as needed.
Below is a statement from HemoCue President, Christophe Duret, about our company’s response and operational impact from the COVID-19 outbreak.
To ensure we minimize disruption in our services provided, please contact your local representative for questions related to order and delivery.
The HemoCue analyzers should be cleaned according the cleaning instructions described in the operating manual. In addition, it is important to ensure that local environmental cleaning and disinfection procedures are followed consistently and correctly. Medical devices and equipment should be managed in accordance with safe routine procedures.
For further guidance, specifically when contamination of equipment with the Novel Coronavirus (SARS-CoV-2) is suspected, please see the latest recommendations issued by the European Centre for Disease Prevention and Control (ECDC) here and the World Health Organization (WHO) here.
Following the COVID-19 travel restrictions and WHO social distancing recommendations, we have decided to cancel our participation in upcoming congresses and other industry events until end of Q2 2020.
Follow our updates under Exhibitions & Meetings below.
During this difficult time, where the COVID-19 outbreak forces many of us to stay at home to protect one another, we would like to support you with relevant material on our different channels.
Did you know that you can find HemoCue Knowledge Center on our website? We have a selection of online training, educational presentations, white papers, scientific summaries, recorded webinars and more to improve and deepen your knowledge.
One of the benefits of using this POCT, instead of sending the sample to the lab, is the massive reduction in detection time. This new rapid POCT gives the medical professional a result within 45 minutes instead of hours or days (i.e. compared to laboratory testing). Learn more about the new test here.
Lately, IDT has also achieved large-scale manufacturing of their key component, which will enable COVID-19 testing for millions of Americans. Learn about IDT and their work here.
“It must be possible”. This conviction has been the driving force behind HemoCue since the beginning more than 35 years ago. Never giving up, never compromising and a problem-solving focus has been the HemoCue way of working.
Today, we are facing a new type of challenge, which we share with the rest of the world. Let us join forces, follow recommendations from health authorities and continue the fight together. “It must be possible” - this time to fight the COVID-19.
Take care, stay safe and healthy!
HemoCue
At HemoCue we are - in our own way - contributing to the fight against COVID-19 by ensuring continued supply of our point-of-care analyzers, e.g. HemoCue® WBC DIFF System, HemoCue® Hb Systems and HemoCue® Glucose 201 Systems - into primary care units, emergency departments (ED) and other front-line healthcare settings.
We have seen how front-line medical staff use HemoCue® WBC DIFF System to assist in discrimination between viral or bacterial infections, and deciding on sending the patient home or referring to hospital. Our analyzers are e.g. in use by mobile teams visiting patients at home and by staff within the elderly care.
